Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Haifaa Abdulhaq, Andrew Hwang & Omar Mahmood. (2023) Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context. OncoTargets and Therapy 16, pages 617-629.
Read now
Read now
Magalie Tardif, Amalia Souza, Maja Krajinovic, Henrique Bittencourt & Thai Hoa Tran. (2021) Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy 22:14, pages 1871-1887.
Read now
Read now
Marie Balsat, Victoria Cacheux, Martin Carre, Emmanuelle Tavernier-Tardy & Xavier Thomas. (2020) Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Expert Review of Anticancer Therapy 20:10, pages 879-891.
Read now
Read now
Magdalena Witkowska, Piotr Smolewski, Agata Majchrzak & Tadeusz Robak. (2016) Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?. Expert Opinion on Drug Discovery 11:11, pages 1033-1045.
Read now
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Read now
Tadeusz Robak. (2014) Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Review of Hematology 7:6, pages 841-857.
Read now
Read now
Articles from other publishers (32)
Zi-Han Ye, Wei-Bang Yu, Mu-Yang Huang, Jun Chen & Jin-Jian Lu. (2023) Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B 13:4, pages 1467-1487.
Crossref
Crossref
David Sermer, Pavania Elavalakanar, Jeremy S. Abramson, M. Lia Palomba, Gilles Salles & Jon Arnason. (2023) Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation. Blood Reviews 57, pages 101002.
Crossref
Crossref
Si Wang, Xing Yan, Chang Yang & Hua Naranmandura. (2022) The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions. Bioengineering 9:11, pages 635.
Crossref
Crossref
Sarah Bailly, Guillaume Cartron, Sridhar Chaganti, Raul Córdoba, Paolo Corradini, Johannes Düll, Isacco Ferrarini, Wendy Osborne, Andreas Rosenwald, Juan‐Manuel Sancho, Hervé Tilly, Eric Van Den Neste, Andreas Viardot & Carlo Visco. (2022) Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper. Hematological Oncology 40:4, pages 505-517.
Crossref
Crossref
Stefania Bramanti, Matteo Carrabba, Alice Di Rocco, Elena Fabris, Luca Gastaldi, Paolo Locatelli & Maria Chiara Tisi. (2022) Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project. Global & Regional Health Technology Assessment 9, pages 1-8.
Crossref
Crossref
Pier Luigi Zinzani & Giorgio Minotti. (2021) Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology 148:1, pages 177-190.
Crossref
Crossref
Yu-Chi Chen, Wei Shi, Jia-Jie Shi & Jin-Jian Lu. (2021) Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective. Journal of Cancer Research and Clinical Oncology 148:1, pages 1-14.
Crossref
Crossref
Colleen Annesley & Rebecca Gardner. 2022. Clinical Management of Acute Lymphoblastic Leukemia. Clinical Management of Acute Lymphoblastic Leukemia
353
372
.
Sun Min Lim, Kyoung-Ho Pyo, Ross A Soo & Byoung Chul Cho. (2021) The promise of bispecific antibodies: Clinical applications and challenges. Cancer Treatment Reviews 99, pages 102240.
Crossref
Crossref
O. A. Vynnytska, O. I. Dorosh, L. Ya. Dubey & N. V. Dubey. (2021) Immunophenotypic Profile of Blast Cells as a Marker for Diagnosis of Relapsed Children Acute Lymphoblastic Leukemia. Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 6:1, pages 56-64.
Crossref
Crossref
Johannes Düll, Max Topp & Gilles Salles. (2021) The use of tafasitamab in diffuse large B-cell lymphoma. Therapeutic Advances in Hematology 12, pages 204062072110274.
Crossref
Crossref
Kumudhini Preethi Haran, Alexandra Lockhart, Ailian Xiong, Enrico Radaelli, Patrick J. Savickas, Avery Posey & Nicola J. Mason. (2020) Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes. Veterinary Pathology 57:2, pages 241-252.
Crossref
Crossref
Nitin JainWendy StockAmer ZeidanEhab AtallahJames McCloskeyLeonard HeffnerBenjamin TomlinsonBhavana BhatnagarJay FeingoldDavid UngarGrace ChaoXiaoyan ZhangYajuan QinKarin Havenith, Hagop Kantarjian & Matthew J. Wieduwilt. (2020) Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Advances 4:3, pages 449-457.
Crossref
Crossref
Sarah A. Holstein & Matthew A. Lunning. (2019) CAR T‐Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clinical Pharmacology & Therapeutics 107:1, pages 112-122.
Crossref
Crossref
Patrick Schlegel, Gundram Jung, Anne-Marie Lang, Michaela Döring, Johannes H. Schulte, Martin Ebinger, Ursula Holzer, Florian Heubach, Christian Seitz, Barbara Lang, Patrick Hundsdörfer, Angelika Eggert, Thomas Eichholz, Hermann Kreyenberg, Peter Lang & Rupert Handgretinger. (2019) ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. Bone Marrow Transplantation 54:S2, pages 689-693.
Crossref
Crossref
Hasan Uludag, Anyeld Ubeda & Aysha Ansari. (2019) At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids. Frontiers in Bioengineering and Biotechnology 7.
Crossref
Crossref
Lavinia IonescuSimon Urschel. (2019) Memory B Cells and Long-lived Plasma Cells. Transplantation 103:5, pages 890-898.
Crossref
Crossref
Francesco Ceppi & Rebecca A. Gardner. (2019) Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia. The Cancer Journal 25:3, pages 191-198.
Crossref
Crossref
Dionysos Slaga, Diego Ellerman, T. Noelle Lombana, Rajesh Vij, Ji Li, Maria HristopoulosRobyn Clark, Jennifer Johnston, Amy SheltonElaine MaiKapil GadkarAmy A. Lo, James T. Koerber, Klara TotpalRodney PrellGenee LeeChristoph Spiess & Teemu T. Junttila. (2018) Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Science Translational Medicine 10:463.
Crossref
Crossref
Zhuanglin Li, Mingxue Wang, Xuejing Yao, Huanzhao Li, Shenjun Li, Lina Liu, Deling Yu, Xue Li, Jianmin Fang & Changjiang Huang. (2018) Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment. International Immunopharmacology 62, pages 299-308.
Crossref
Crossref
Vanessa Buatois, Zoë Johnson, Susana Salgado-Pires, Anne Papaioannou, Eric Hatterer, Xavier Chauchet, Françoise Richard, Leticia Barba, Bruno Daubeuf, Laura Cons, Lucile Broyer, Matilde D'Asaro, Thomas Matthes, Simon LeGallou, Thierry Fest, Karin Tarte, Robert K. Clarke Hinojosa, Eulàlia Genescà Ferrer, José María Ribera, Aditi Dey, Katharine Bailey, Adele K. Fielding, Linda Eissenberg, Julie Ritchey, Michael Rettig, John F. DiPersio, Marie H. Kosco-Vilbois, Krzysztof Masternak, Nicolas Fischer, Limin Shang & Walter G. Ferlin. (2018) Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics 17:8, pages 1739-1751.
Crossref
Crossref
Elaine Vickers. 2018. A Beginner's Guide to Targeted Cancer Treatments. A Beginner's Guide to Targeted Cancer Treatments
259
312
.
Patrick A. Baeuerle. 2018. Successful Drug Discovery. Successful Drug Discovery
111
130
.
Colleen E. Annesley, Corinne Summers, Francesco Ceppi & Rebecca A. Gardner. (2017) The Evolution and Future of CAR T Cells for B‐Cell Acute Lymphoblastic Leukemia. Clinical Pharmacology & Therapeutics 103:4, pages 591-598.
Crossref
Crossref
Rashmi Kumar. 2018. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
513
522
.
Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps & Dennis Benjamin. (2017) Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood 130:18, pages 2018-2026.
Crossref
Crossref
R. Ajina, D. AlDeghaither, S. Jablonski & L.M. Weiner. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
32
65
.
Christian Schütz, Juan Carlos Varela, Karlo Perica, Carl Haupt, Mathias Oelke & Jonathan P. Schneck. (2016) Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget 7:42, pages 68503-68512.
Crossref
Crossref
J Weiland, D Pal, M Case, J Irving, F Ponthan, S Koschmieder, O Heidenreich, A von Stackelberg, C Eckert, J Vormoor & A Elder. (2016) BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance. Leukemia 30:9, pages 1920-1923.
Crossref
Crossref
Rashmi Kumar. 2017. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
1
10
.
Rosalba Camicia, Hans C. Winkler & Paul O. Hassa. (2015) Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular Cancer 14:1.
Crossref
Crossref
Ofir Wolach & Richard M. Stone. (2015) Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research 21:19, pages 4262-4269.
Crossref
Crossref